Is this a Prime Time To acquire Harmony Biosciences Holdings Inc. (HRMY) stock

After finishing at $41.50 in the prior trading day, Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) closed at $40.64, down -2.07%. In other words, the price has decreased by -$0.86 from its previous closing price. On the day, 507214 shares were traded. HRMY stock price reached its highest trading level at $41.24 during the session, while it also had its lowest trading level at $40.06.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



Our goal is to gain a better understanding of HRMY by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.39. For the most recent quarter (mrq), Quick Ratio is recorded 5.00 and its Current Ratio is at 5.10. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.47.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on October 14, 2022, Upgraded its rating to Buy and sets its target price to $61 from $57 previously.

On October 14, 2022, Janney Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $57 to $61.

Jefferies Downgraded its Buy to Hold on August 03, 2022, while the target price for the stock was maintained at $57.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 14 when Nielsen Jack sold 2,834 shares for $59.96 per share. The transaction valued at 169,927 led to the insider holds 2,571,024 shares of the business.

Wicki Andreas sold 130 shares of HRMY for $7,800 on Dec 14. The Director now owns 2,147,943 shares after completing the transaction at $60.00 per share. On Dec 13, another insider, Wicki Andreas, who serves as the Director of the company, sold 6,320 shares for $60.13 each. As a result, the insider received 380,022 and left with 2,148,073 shares of the company.

Valuation Measures:

As of this moment, Harmony’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.71, and their Forward P/E ratio for the next fiscal year is 11.18. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.73 while its Price-to-Book (P/B) ratio in mrq is 5.99.

Stock Price History:

Over the past 52 weeks, HRMY has reached a high of $62.08, while it has fallen to a 52-week low of $33.04. The 50-Day Moving Average of the stock is 47.12, while the 200-Day Moving Average is calculated to be 50.03.

Shares Statistics:

The stock has traded on average 576.72K shares per day over the past 3-months and 536.95k shares per day over the last 10 days, according to various share statistics. A total of 59.42M shares are outstanding, with a floating share count of 58.29M. Insiders hold about 1.49% of the company’s shares, while institutions hold 93.10% stake in the company. Shares short for HRMY as of Jan 30, 2023 were 5.09M with a Short Ratio of 5.80M, compared to 4.37M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 8.57% and a Short% of Float of 17.72%.

Earnings Estimates

Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of $0.58 for the current quarter, with a high estimate of $0.81 and a low estimate of $0.47, while EPS last year was $0.38. The consensus estimate for the next quarter is $0.51, with high estimates of $0.63 and low estimates of $0.42.

Analysts are recommending an EPS of between $2.79 and $2.66 for the fiscal current year, implying an average EPS of $2.72. EPS for the following year is $2.7, with 8 analysts recommending between $3.18 and $2.21.

Revenue Estimates

8 analysts predict $127.34M in revenue for the current quarter. It ranges from a high estimate of $129.5M to a low estimate of $123.5M. As of the current estimate, Harmony Biosciences Holdings Inc.’s year-ago sales were $91.21M, an estimated increase of 39.60% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $116.16M, an increase of 36.20% less than the figure of $39.60% in the same quarter last year. There is a high estimate of $120M for the next quarter, whereas the lowest estimate is $112.04M.

A total of 8 analysts have provided revenue estimates for HRMY’s current fiscal year. The highest revenue estimate was $439.1M, while the lowest revenue estimate was $433M, resulting in an average revenue estimate of $436.87M. In the same quarter a year ago, actual revenue was $305.44M, up 43.00% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $580.42M in the next fiscal year. The high estimate is $624.6M and the low estimate is $537.07M. The average revenue growth estimate for next year is up 32.90% from the average revenue estimate for this year.